Biosensors   

Is Biosensors a good buy?

today is the best day to test Biosensor support and resistance, 0.69 versus 0.80.

let's see who will win today, round 1 .... fight !

 

Keep the $, don't touch BIG at this moment, it don't worth the efforts and money. Beou the bugger next yr Mar. Cheers.

 

This could b good news to BIG.... heehee..

Boston Scientific 4Q Posts $458M Loss.

Stent sales at Boston Scientific and a rival, Johnson & Johnson, have been hurt by research questioning the devices' safety and effectiveness, although some more recent studies have called some of the findings into question.

http://biz.yahoo.com/ap/080205/earns_boston_scientific.html


 

 

gbleng Member	Posted: 05-Feb-2008 11:07
x 0 x 0	Hey Bengster, what do you think of a BIG, Terumo-Medtronic..mega M&A... make sense? BIG seems to be the common denominator with CFO and CEO connection.... realistic or a pipe dream??? Haha have a great new year ahead to all BIG supporters!!!

Since Medtronic has influence on about 25% of BIG's enlarge share capital, I think it is Terumo that will be more keen to do open market purchase on BIG's shares at the moment. I will not be surprise to see Terumo suddenly announce they become a substantial shareholder of BIG. Terumo does not want unfavourable hostile takeover of BIG that will affect Terumo's marketing plans of their NOBORI DES in CE approved markets. NOBORI and BIOMATRIX will compete with each other in these markets. So by holding a substantial stake in BIG, they can have some influence and negotiate some "terms" with the takeover offerer on CE approved markets before Terumo agree to support the takeover offer. This is to safeguard Terumo's interest and also to make some "quick" bucks as BIG is considered cheap at current share price and takeover could mean multi-bagger investment for Terumo as well.  

 

OCBC Investment Research Pte Ltd

Biosensors Int?l Ltd

As expected 3Q08. Biosensors reported a marginal 5% YoY increase in revenue to US$8.7m and continued its unprofitable situation with a US$7.8m loss. Gross margin improved to 46% (vs. 38% in 3Q07) as Biosensors sold more Bare Metal Stents (BMS) in Japan and other Asian countries. The results were in line with our expectations.

Terumo, the tricky piece. Looking ahead, we view Biosensors' relationship with Terumo as a deciding factor in the magnitude of its earnings acceleration. The conundrum now is that Terumo has a non-exclusive distribution right (excl. JP and US) to sell its NOBORI DES (uses Biosensors' technology) where Biosensors is also pursuing sales of its BioMatrix DES in the same regions. Terumo has a wider marketing footprint while Biosensors is limited in this aspect. Biosensors' lucrative revenue sharing deal with Terumo can possibly give it better operating margins but it must also plough the field to ensure the BioMatrix brand is being seeded in the market to ensure its longevity.

New management, new horizons. After our lunch meeting with Biosensors' new CEO, Michael Kleine, we are confident that he is the change agent that will be able to carry Biosensors through this phase of operational execution. His pedigree of successfully growing medical device companies and handling M&As will bode well for Biosensors. In particular, we feel that he can open up new horizons with his experience with neuro related products in the future. Michael's stint at MicroVention (Terumo subsidiary) is a double edged sword as he brings to Biosensors immediate management knowledge and ethos of Terumo but will also need to carefully navigate pursuing the same markets against his ex-employer.

Proving its mettle.

http://www.remisiers.org/research//Biosensors-080205-OIR.pdfBiosensors has eliminated the CE mark overhang and must prove its mettle in future operational excellence. We still like the group for its strong IP position, timely entry into the booming Chinese DES market as well as continued favourable opinions of clinical thought leaders on its DES system. We believe further authentication of BioMatrix through high level clinical conferences will be able to accelerate its visibility and earnings. Maintain BUY with fair value of S$1.23.

 

OCBC Investment Research Pte Ltd

Holding on to an uptrend

- Biosensors has corrected to a support level which has been set by the

uptrend line that was formed between Aug to Dec 07.

- We observed that the traded volume had been on a gradual decline as the

price correction progressed over the last 2 weeks. We are now witnessing

a minor consolidation take place at the uptrend line.

- Biosensors has been forming higher highs and higher lows over the last 5

months, suggesting an establishment of a medium-term uptrend.

- The stochastic indicator has fallen into oversold regions indicating a high

probability that we could witness a rebound unfold over the near-term

should the current support level on the uptrend line hold.

- A break below the uptrend line would push Biosensors down towards a

support of S$0.68. Resistance set at S$0.85.

 http://www.remisiers.org/research//Technical%20Analysis%20-%20Biosensors%20-%20080205%20-%20OIR.pdf

 

The analyst from OCBC is strange. Before CE Mark tp is $1.40. After Ce Mark its $1.23 because he/she states that as the company itself states that there will be losses for 2009 the TP is $1.23. After the results and the guidance that the company may return to profitablity..."outlook better as company closer to returning to profitability...." PLUS the fact that Michael Kleine ...bodes well for the company....change agent....etc etc...RETAINS BUY CALL OF $1.23.They talk of M & A etc...but don't factor in the price ...sheesh...really must be patient.

 

movement within the tight range

 

haiz...BB dont want this fellow to go up lar.... still collecting i suspect.....

 

0414 GMT [Dow Jones] Biosensors (B20.SG) off 0.7% at S$0.765, still locked in sideways trading pattern of past 2 weeks after January spike on news company has won coveted CE mark for its flagship BioMatrix drug-eluting stent. Still, outlook for shares looking better as company closer to returning to profitability, with bottomline for fiscal 3Q08 ended December at net loss of US$7.8 million vs US$10.4 million loss year earlier due to higher margins. OCBC Investment Research says recent appointment of new CEO Michael Kleine should bode well for growth; "we are confident that he is the change agent that will be able to carry Biosensors through this phase of operational execution. His pedigree of successfully growing medical device companies and handling M&As will bode well for Biosensors." Retains Buy call, S$1.23 fair value. Support tipped at last week''s low of S$0.735. (FKH)

 

Hey Bengster, what do you think of a BIG, Terumo-Medtronic..mega M&A... make sense? BIG seems to be the common denominator with CFO and CEO connection.... realistic or a pipe dream??? Haha have a great new year ahead to all BIG supporters!!!

 

From OCBC :

Biosensors International Group (Biosensors) reported results that were in line with our expectations with a marginal 5% YoY increase in revenue to US$8.7m and continued its unprofitable situation with a US$7.8m loss. We think that Biosensors? relationship with Terumo will be the deciding factor in the magnitude of its earnings acceleration. Although Biosensors? lucrative revenue sharing deal with Terumo can possibly give it better operational margins, it must also plough the field to ensure the BioMatrix brand is being seeded in the market to ensure its longevity. We are positive on the new CEO, Michael Kleine, as he brings on board his experience in growing medtech companies. We still like Biosensors for its strong IP position, timely entry into the booming Chinese DES market as well as continued favourable opinions of clinical thought leaders on their DES system. We believe further authentication of BioMatrix through high level clinical conferences will be able to accelerate its visibility and earnings. Maintain BUY with fair value of S$1.23.

 

I really don't inderstand this share. My VERY astute investor friend who specializes in US stocks says with such a positive guidance going forward, this share should be going up...must wait for the reports from the analysts. Anyone has any from the usual? Like ocbc,UBS,CS,Citi????

 

breakout or not, need to break 80c 1st else i dun bother..

 

brother, high chance breakout liao.. or someone playing again.

320 lots at 0.76 buy

563 lots at 0.755 buy

580 lots at 0.75 buy,  heee.. market depth is good to read the hidden players, kekekekeke...

 

I read from page 1 to the end of the report last whole night.

it has great potential with all the new hirings... should not miss this boat again..

but too bad, the price didn't go down today, but i will wait a little while to enter.. heee...

 

or u mean Bio-Treat  so close every time see wrongly.....

 

hey JackJames...have u read their FINANCIAL STATEMENT AND DIVIDEND ANNOUNCEMENT

 

 

i hope to see some gam chong spider selling.... 0.73 ? or 0.69 for us to collect ? heee heee.. evil smiles..

 

Excluding a one-time charge of US$1.4m for impairment of reserves, their operating net loss would only be US$6.4m

Assuming that all expenses, ie admin, R &D etc, remain approx constant the next few quarters, then I believe that BIG would only need to have sales of their Bio-matrix to be approx US$10-12m  per quarter, for them to break even.

I am assuming that their gross margin is approx 60 %, which translates to a gross profit of US$6-7.2m. (which is conservative as their China Excel DEs commands gross mgm of 70 % or more).

IF this gross profit of US$6-7.2m flows down to the bottom line, then they would break even.

Not a difficult thing to do, considering that Conors did about US$10m sales per qtr, once they got the CE mark.

All the above are asumptions - Not a call to buy/sell